Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vinorelbine liposomal - Taiwan Liposome Company

Next Previous
Drug Profile

Vinorelbine liposomal - Taiwan Liposome Company

Alternative Names: Nanoliposomal vinorelbine - Taiwan Liposomal Company; TLC-178; Vinorelbine encapsulated liposome - TLC

Latest Information Update: 28 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma; Soft tissue sarcoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • No development reported Non-Hodgkin's lymphoma; Rhabdomyosarcoma

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for preclinical development in Rhabdomyosarcoma in USA (Parenteral)
  • 31 Dec 2020 Taiwan Liposome Company has patent protection covering the composition of matter of vinorelbine liposomal in Taiwan, China/Hong Kong, Japan, South Korea, Australia, USA and European countries, prior to December 2020
  • 31 Dec 2020 Taiwan Liposome Company has patent protection for vinorelbine liposomal in USA, European and Asia markets, prior to December 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top